Tardive dyskinesia causes involuntary movements in some people taking antipsychotic medications. Here’s what you need to know about this movement disorder. Antipsychotic medications are a mainstay of ...

While tardive dyskinesia is most often caused by sustained exposure to antipsychotics, any drug that significantly blocks dopamine receptors can be a culprit, said Demian Rose, MD, PhD, of the ...

Tardive dyskinesia (TD) can cause uncontrollable jerking movements of the face, arms, or legs. It typically develops due to the use of certain medications. Tardive dyskinesia (TD) is a rare type of ...

1) Tardive syndrome (TS) is an umbrella term that can include “the spectrum of all persistent hyperkinetic, hypokinetic and sensory phenomenologies resulting from chronic dopamine receptor blocking ...

The symptoms of this involuntary movement disorder can trigger embarrassment and self-consciousness, but there are ways to manage symptoms. If you have tardive dyskinesia, a side effect associated ...

Kristin Weiland is a documentary film producer and writer with a background in crisis management and ethnographic research. She specializes in investigative and social impact documentary projects, and ...

Tardive dyskinesia is a movement disorder that causes repetitive, involuntary movements in the face, neck, arms, and legs. The condition is a side effect of certain medications. Symptoms can improve ...

Tardive dyskinesia (TD) is a movement disorder typically caused by taking neuroleptic drugs. Treatment focuses on preventing the recurrence or persistence of symptoms. Tardive dyskinesia (TD) most ...

Tardive dyskinesia is a drug-induced neurological disorder characterized by involuntary movements of the face and body. The ...

The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from ...

Tardive dyskinesia (TD) is a severe and often irreversible movement disorder resulting from prolonged exposure to dopamine receptor-blocking agents (DRBAs), most notably antipsychotics. Characterized ...

SAN DIEGO, Nov. 14, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the full manuscript of the long-term safety and efficacy data from the blinded KINECT 3 Phase ...